Calithera Biosciences Stock Net Income
| CALA Stock | USD 0.0002 0.00 0.00% |
As of the 16th of February 2026, Calithera Biosciences shows the Downside Deviation of 70.35, risk adjusted performance of 0.1138, and Mean Deviation of 21.7. Calithera Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Calithera Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Calithera Biosciences' valuation are provided below:Calithera Biosciences does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Calithera |
Calithera Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Calithera Biosciences' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Calithera Biosciences.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Calithera Biosciences on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Calithera Biosciences or generate 0.0% return on investment in Calithera Biosciences over 90 days. Calithera Biosciences is related to or competes with Unidoc Health, and Devonian Health. Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of sm... More
Calithera Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Calithera Biosciences' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Calithera Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 70.35 | |||
| Information Ratio | 0.1273 | |||
| Maximum Drawdown | 280.0 | |||
| Value At Risk | (50.00) | |||
| Potential Upside | 100.0 |
Calithera Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Calithera Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Calithera Biosciences' standard deviation. In reality, there are many statistical measures that can use Calithera Biosciences historical prices to predict the future Calithera Biosciences' volatility.| Risk Adjusted Performance | 0.1138 | |||
| Jensen Alpha | 5.87 | |||
| Total Risk Alpha | 2.39 | |||
| Sortino Ratio | 0.0794 | |||
| Treynor Ratio | (1.50) |
Calithera Biosciences February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1138 | |||
| Market Risk Adjusted Performance | (1.49) | |||
| Mean Deviation | 21.7 | |||
| Semi Deviation | 20.34 | |||
| Downside Deviation | 70.35 | |||
| Coefficient Of Variation | 775.67 | |||
| Standard Deviation | 43.88 | |||
| Variance | 1925.12 | |||
| Information Ratio | 0.1273 | |||
| Jensen Alpha | 5.87 | |||
| Total Risk Alpha | 2.39 | |||
| Sortino Ratio | 0.0794 | |||
| Treynor Ratio | (1.50) | |||
| Maximum Drawdown | 280.0 | |||
| Value At Risk | (50.00) | |||
| Potential Upside | 100.0 | |||
| Downside Variance | 4948.89 | |||
| Semi Variance | 413.64 | |||
| Expected Short fall | (125.00) | |||
| Skewness | 2.17 | |||
| Kurtosis | 7.52 |
Calithera Biosciences Backtested Returns
Calithera Biosciences is out of control given 3 months investment horizon. Calithera Biosciences secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-four different technical indicators, which can help you to evaluate if expected returns of 6.02% are justified by taking the suggested risk. Use Calithera Biosciences Risk Adjusted Performance of 0.1138, downside deviation of 70.35, and Mean Deviation of 21.7 to evaluate company specific risk that cannot be diversified away. Calithera Biosciences holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -3.76, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Calithera Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Calithera Biosciences is expected to outperform it. Use Calithera Biosciences treynor ratio, downside variance, and the relationship between the total risk alpha and value at risk , to analyze future returns on Calithera Biosciences.
Auto-correlation | -0.06 |
Very weak reverse predictability
Calithera Biosciences has very weak reverse predictability. Overlapping area represents the amount of predictability between Calithera Biosciences time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Calithera Biosciences price movement. The serial correlation of -0.06 indicates that barely 6.0% of current Calithera Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.06 | |
| Spearman Rank Test | -0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Calithera Biosciences reported net income of (39.65 Million). This is 111.62% lower than that of the Biotechnology sector and 156.61% lower than that of the Health Care industry. The net income for all United States stocks is 106.94% higher than that of the company.
Calithera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calithera Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Calithera Biosciences could also be used in its relative valuation, which is a method of valuing Calithera Biosciences by comparing valuation metrics of similar companies.Calithera Biosciences is currently under evaluation in net income category among its peers.
Calithera Fundamentals
| Return On Equity | -1.14 | |||
| Return On Asset | -0.56 | |||
| Current Valuation | (1.1 M) | |||
| Shares Outstanding | 4.87 M | |||
| Shares Owned By Insiders | 1.07 % | |||
| Shares Owned By Institutions | 26.76 % | |||
| Number Of Shares Shorted | 417.28 K | |||
| Price To Earning | (14.08) X | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 1.71 X | |||
| Gross Profit | (42.7 M) | |||
| EBITDA | (43.77 M) | |||
| Net Income | (39.65 M) | |||
| Cash And Equivalents | 41.79 M | |||
| Cash Per Share | 8.59 X | |||
| Total Debt | 1.67 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 4.82 X | |||
| Book Value Per Share | (0.40) X | |||
| Cash Flow From Operations | (43.61 M) | |||
| Short Ratio | 0.78 X | |||
| Earnings Per Share | (1.59) X | |||
| Price To Earnings To Growth | (0.29) X | |||
| Target Price | 5.0 | |||
| Beta | 0.25 | |||
| Market Capitalization | 341.07 K | |||
| Total Asset | 28.68 M | |||
| Retained Earnings | (512.62 M) | |||
| Working Capital | 19.23 M | |||
| Current Asset | 72.5 M | |||
| Current Liabilities | 3.83 M | |||
| Z Score | -29.14 | |||
| Net Asset | 28.68 M |
About Calithera Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calithera Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calithera Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calithera Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Calithera Pink Sheet
Calithera Biosciences financial ratios help investors to determine whether Calithera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Calithera with respect to the benefits of owning Calithera Biosciences security.